Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on November 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in settlement numbers since 2013 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the class period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, which could jeopardize PYLARIFY's revenue and growth potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the relevant period [2]. Group 2: Legal Process and Investor Information - Investors in Lantheus have until November 10, 2025, to seek appointment as lead plaintiff in the class action, which involves directing the litigation on behalf of all class members [3]. - A lead plaintiff is typically the investor or group of investors with the largest financial interest in the case, and they will select counsel to represent the class [3]. - Investors who have suffered significant losses are encouraged to contact Kessler Topaz Meltzer & Check, LLP for more information regarding the lawsuit [4].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Lantheus and certain o ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). DEADLINE: November 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-form-2/? id=172698&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of LNTH ...

Core Insights - Global equity markets experienced broad positive returns in Q3 2025, driven by resilient corporate earnings, enthusiasm for AI, and the U.S. Federal Reserve's first interest rate cut of the year [3][21] - Emerging markets, particularly China, led the gains, supported by a U.S. trade truce and strength in the tech sector [3][4] - The Polaris Global Equity Composite gained 5.04% (net of fees) for the quarter, underperforming the MSCI World Index, which returned 7.36% [5][6] Market Performance - Developed markets saw weaker currencies benefiting export-oriented indices, with Japan's TOPIX Index up 11.0% and the U.K.'s FTSE All-Share Index up 6.9% [4] - The U.S. market, represented by the S&P 500 Index, gained over 8%, primarily due to tech and communication stocks [4] - France and Germany underperformed due to geopolitical and fiscal concerns, with tepid growth projections under new U.S. trade policy [4] Sector Analysis - The healthcare sector was the best performer, with notable gains from pharmaceutical stocks, while financials, consumer discretionary, and IT also contributed positively [5][6] - Health insurers faced challenges, with UnitedHealth Group and CVS Health posting over 10% returns, while Elevance Health's shares dropped sharply due to profit guidance cuts [7] - In IT, Samsung Electronics excelled with strong performance in HBM technology and a significant deal with Tesla for AI chip manufacturing [11] Company Highlights - United Therapeutics Corp. was a top contributor to portfolio performance, driven by positive clinical trial results for its drug Tyvaso, potentially adding $4-5 billion in peak sales [6] - AbbVie, Inc. expects high single-digit revenue growth through 2029, with flagship drugs projected to exceed $31 billion in sales by 2027 [6] - The Carlyle Group Inc. outperformed in the financial sector, up over 20% due to strong fee-based credit and secondaries business [8] Investment Strategy - The current economic environment is characterized by a "two-speed" economy, with a concentrated AI-driven boom amidst subdued growth in other sectors [21][22] - Financials are seen as attractive due to stable net interest margins and loan growth, while defensives like consumer staples and healthcare are expected to perform well [22] - Opportunities in economically-sensitive sectors are being explored, with a focus on industrials benefiting from AI integration and supply chain modernization [22][23]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on November 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to accurately assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not properly disclose the implications of a price increase in early 2025, which was issued despite previous price erosion, potentially jeopardizing PYLARIFY's pricing, revenue, and growth prospects [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the Class Period [2]. Group 2: Legal Process and Investor Participation - Investors in Lantheus have until November 10, 2025, to seek appointment as lead plaintiff in the class action, representing the interests of all class members [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case, who will select counsel to represent the class [3]. - Participation as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the class action and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4]. - The firm encourages Lantheus investors who have experienced losses to contact them for more information regarding the lawsuit [4].

Accessibility StatementSkip Navigation NEW YORK, Oct. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https: ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Lantheus Holdings, Inc. about a class action lawsuit related to misleading statements regarding the company's revenue outlook and market dynamics [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from February 26, 2025, to August 5, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to contact the firm for potential lead plaintiff appointment [1][4]. Allegations - The complaint alleges that Lantheus made false statements and concealed information about its revenue outlook and growth potential [3]. - It is claimed that the company misrepresented its understanding of the competitive dynamics and pricing of its product, Pylarify, leading to an inflated perception of its market performance [3]. Next Steps for Shareholders - Shareholders must register by November 10, 2025, to participate in the class action [4]. - Once registered, shareholders will receive updates on the case through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors from deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Points - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position [7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, statements made by the defendants about the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].